Those studies for which published data has been augmented by additional information are so labelled in Table 1. Studies used assays with widely varying cut-offs for the detection of HBV (Table 1). This could have introduced bias, with the use of more sensitive assays resulting in an apparent lower rate of suppression. However plotting the proportion www.selleckchem.com/products/kpt-330.html undetectable against the logarithm of the cut-off value showed no clear pattern (Figure 3) and the cut-off was ignored in further analyses. Figure 3 Log of HBV viral load assay cut-off against proportion undetectable at one year. The overall proportion suppressed was 57.4% (95% CI: 53.0�C61.7%), 79.0% (95% CI: 73.6�C83.8%), and 85.6% (95% CI: 79.2�C90.7%) after one, two, and three years of treatment with TDF (Table 3). Table 3 Suppression at yearly time points.

It was possible to assess rates of virological suppression by HBeAg status for patients from ten of the included studies. [6], [8], [13], [14], [19], [21]�C[23], [25], [27] For HBeAg positive and negative patients respectively the proportion fully suppressed was 51.8%, 82.0%, 86.6% and 76.3%, 82.1%, 75.0% at one, two and three years (Figure 4). After one year of treatment, a higher proportion of HBeAg negative than HBeAg positive individuals had a fully suppressed HBV viral load (p=0.005). However, after one year the rates of suppression were not significantly different. Figure 4 Percentage with undetectable HBV viral load over time, by HBeAg status. Table 4 shows the effects of prior and concomitant 3TC/FTC on virological suppression.

Effects are given for all patients and also stratified by prior or concomitant treatment with 3TC/FTC as appropriate. Overall, at one year prior exposure to 3TC had an odds ratio of 0.69 (95% CI: 0.45 to 1.08) and treatment with 3TC/FTC in addition to TDF of 1.24 (95% CI: 0.68 to 2.24), neither being statistically significant. The effect of prior exposure to 3TC/FTC was similar, but also not statistically significant, at each of one, two, and three years. The effect of concomitant treatment with 3TC/FTC favoured dual therapy at one year but TDF monotherapy at years two and three, but these effects were again not statistically significant. The odds ratios in the stratified analyses were similar to the effects overall but with even wider confidence intervals. There was no evidence of an interaction between prior and concomitant 3TC/FTC treatment (p=0.98 at 1 year, p=0.14 at 2 years and p=0.99 at 3 years). Between-study heterogeneity, Dacomitinib allowing for the effects of prior and concomitant 3TC/FTC treatment, was significant (p<0.01) at year 1 but not at year 2 (p=0.48) or at year 3 (p=1.0).